Bibf 1120; Nintedanib NEW

Factory Provide Anti-Cancer Bibf 1120 CAS 928326-83-4 Nintedanib Powder

Introduction

Product Name : Bibf 1120

Other name:Nintedanib;BIBF-1120;BIBF-1120(Vargatef);VARGATEF ( BIBF1120 );

CAS No.:928326-83-4

MF:C31H33N5O4

Purity :99%

MW:539.633

Appearance: white to off white powder

Storage :Sealed in dry,Sealed in dry,Room Temperature

Nintedanib is the first approved drug for the management of idiopathic pulmonary fibrosis (IPF), a rare but often fatal lung disease. Nintedanib is believed to exert its mechanism of action by inhibiting multiple receptor tyrosine kinases, including those that have been implicated in the pathogenesis of IPF (i.e., fibroblast growth factor receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor). Nintedanib also inhibits nonreceptor tyrosine kinases, although the contribution of this inhibition in the efficacy of the drug is unknown.

Function and Application 
Nintanib targets platelet-derived growth factor receptors, fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and the adenosine triphosphate ( ATP) binding sites competitively bind, block the signal pathway of fibrosis process, inhibit the proliferation, metastasis and transformation of fibroblasts, thereby slowing the progression of IPF disease.